Mpox Antivirals
Medical Countermeasures for the treatment of mpox
While there are currently no treatments specifically approved for mpox, therapeutics developed for patients with smallpox have been deployed during the 2022 mpox outbreak. Use of Tecovirimat (TPOXX) and other treatments should be considered in patients who may benefit from them. Clinical trials have shown that persons who do not have severe disease or risk factors for severe disease will recover with supportive care and pain management.
CDC's guidance requires the state health department to be included in the request for TPOXX or other medical countermeasures for mpox treatment. Georgia DPH does not retain stores of mpox medical countermeasures, and therefore all requests must ultimately go through CDC with state HD support.
To expedite this process, providers should first review the information at Tecovirimat (TPOXX) for Treatment of Monkeypox to determine eligibility of their patient and to review information on the benefits of TPOXX and other medical countermeasures, Expanded Access Investigational New Drug (EA IND) criteria, and have information available ahead of the consult. Of note, EA IND countermeasures cannot be released without provider participation in this process.
A provider who would like to initiate a request for mpox medical countermeasures - after they have reviewed eligibility criteria and EA IND requirements - should reach out to 1-866-PUB-HLTH (782-4584) to be connected to an epidemiologist to initiate the request with appropriate federal partners.
Page last updated 3/5/26